EV

ETP Ventures

North America, Maryland, United States, Rockville

Description

ETP Ventures offers funding and support in establishing life science firms that create product solutions in drug discovery and medicine.

Investor Profile

ETP Ventures has made 4 investments, with 0 in the past 12 months and 25% as lead.

Stage Focus

  • Series A (50%)
  • Angel (25%)
  • Seed (25%)

Country Focus

  • China (50%)
  • Hong Kong (25%)
  • Switzerland (25%)

Industry Focus

  • Health Care
  • Biotechnology
  • Biopharma
  • Therapeutics
  • Medical
  • Nutrition
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does ETP Ventures frequently co-invest with?

Bold Capital Partners
North America, California, United States, Santa Monica
Co-Investments: 1
Longevity Vision Fund
North America, New York, United States, New York
Co-Investments: 1
Guoqian Venture Capital
Asia, Jiangsu, China, Haimen
Co-Investments: 1
Formic Ventures
North America, California, United States, San Francisco
Co-Investments: 1
HL
North America, California, United States, San Diego
Co-Investments: 1
Huatai Zijin Investment
Asia, Jiangsu, China, Nanjing
Co-Investments: 1
LongeVC
Europe, Ticino, Switzerland, Lugano
Co-Investments: 1
FC Capital
Asia, Shanghai, China, Shanghai
Co-Investments: 1
PPF Group
Europe, Noord-Holland, The Netherlands, Amsterdam
Co-Investments: 1
Emerging Technology Partners
North America, California, United States, San Francisco
Co-Investments: 2

What are some of recent deals done by ETP Ventures?

SEIMEI

Changyang, Beijing, China

SEIMEI is a nutrition and anti-aging biotechnology brand.

Health CareMedicalNutrition
SeedNov 18, 2022
Amount Raised: $4,000,000
Deep Longevity

Hong Kong, Hong Kong Island, Hong Kong

Deep Longevity is a biotechnology company transforming longevity R&D through AI-discovered biomarkers of aging.

BiotechnologyHealth Care
Series AJul 14, 2020
Dima Biotech

Suzhou, Jiangsu, China

Dima Biotech is a cancer immunotherapy and monoclonal antibody developer.

BiotechnologyHealth Care
AngelSep 11, 2019
Cellestia

Basel, Basel-Stadt, Switzerland

Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression.

BiopharmaBiotechnologyHealth CareTherapeutics
Series ADec 19, 2018
Amount Raised: $20,120,502